Reviva Pharmaceuticals Holdings, Inc.
NASDAQ:RVPH

Watchlist Manager
Reviva Pharmaceuticals Holdings, Inc. Logo
Reviva Pharmaceuticals Holdings, Inc.
NASDAQ:RVPH
Watchlist
Price: 1.78 USD 8.54% Market Closed
Market Cap: 59.5m USD
Have any thoughts about
Reviva Pharmaceuticals Holdings, Inc.?
Write Note

Reviva Pharmaceuticals Holdings, Inc.
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Reviva Pharmaceuticals Holdings, Inc.
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
Reviva Pharmaceuticals Holdings, Inc.
NASDAQ:RVPH
Total Other Income
$636.3k
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Total Other Income
-$195m
CAGR 3-Years
N/A
CAGR 5-Years
33%
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Total Other Income
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Total Other Income
$1.1B
CAGR 3-Years
42%
CAGR 5-Years
205%
CAGR 10-Years
-1%
Eli Lilly and Co
NYSE:LLY
Total Other Income
$439.4m
CAGR 3-Years
-18%
CAGR 5-Years
8%
CAGR 10-Years
7%
No Stocks Found

Reviva Pharmaceuticals Holdings, Inc.
Glance View

Market Cap
59.5m USD
Industry
Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. The company is headquartered in Cupertino, California and currently employs 5 full-time employees. The company went IPO on 2018-10-18. The firm discovers, develops and seeks to commercialize therapeutics for various diseases. Its pipeline focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics driven technology platform and chemistry to develop new medicines. Its pipeline has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Its primary focus is developing its lead product candidate, RP5063, for the treatment of schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), behavioral and psychotic symptoms, dementia or Alzheimer's disease (BPSD), Parkinson's disease psychosis (PDP), and attention deficit hyperactivity disorder (ADHD). RP5063 also focuses on the treatment of pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). The firm's RP1208, is in pre-clinical development, which focuses on the treatment of depression and obesity.

RVPH Intrinsic Value
2.42 USD
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Reviva Pharmaceuticals Holdings, Inc.'s Total Other Income?
Total Other Income
636.3k USD

Based on the financial report for Sep 30, 2024, Reviva Pharmaceuticals Holdings, Inc.'s Total Other Income amounts to 636.3k USD.

What is Reviva Pharmaceuticals Holdings, Inc.'s Total Other Income growth rate?
Total Other Income CAGR 3Y
-21%

The average annual Total Other Income growth rates for Reviva Pharmaceuticals Holdings, Inc. have been -21% over the past three years .

Back to Top